Evidence map›Paper›PMID 38222025›Full record

ArticleMultiple sclerosis journal - experimental, translational and clinical

Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme.

T A Hardy, P Aouad, M H Barnett, S Blum, S Broadley, W M Carroll, D Crimmins, D Griffiths, S Hodgkinson, J Lechner-Scott and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 1 country.

T A HardyDepartment of Neurology, Concord Hospital, Concord, NSW, Australia.ORCID https://orcid.org/0000-0003-4145-3172
P AouadNorthern Clinical School, Sharp Neurology and North Shore Private Hospital, University of Sydney, St Leonards, NSW, Australia.
M H BarnettDepartment of Neurology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.ORCID https://orcid.org/0000-0002-2156-8864
S BlumFaculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.ORCID https://orcid.org/0000-0002-2702-3742
S BroadleySchool of Medicine, Gold Coast Campus, Griffith University, Southport, QLD, Australia.ORCID https://orcid.org/0000-0002-9429-4307
W M CarrollDepartment of Neurology, Sir Charles Gairdner Hospital and Perron Institute, Nedlands, WA, Australia.
D CrimminsCentral Coast Neurosciences Research, Erina, NSW, Australia.
D GriffithsCentral Coast MS Clinic, Gosford Hospital, Gosford, NSW, Australia.
S HodgkinsonDepartment of Neurology, Liverpool Hospital, Liverpool, NSW, Australia.
J Lechner-ScottHunter Medical Research Institute, University of Newcastle, New Lambton Heights, NSW, Australia.
A LeeFlinders University College of Medicine and Public Health, Bedford Park, SA, Australia.
R MalhotraCanberra Specialist Centre, Deakin, ACT, Australia.
P McCombeUniversity of Queensland, St Lucia, QLD, Australia.
J ParrattNorthern Clinical School, Sharp Neurology and North Shore Private Hospital, University of Sydney, St Leonards, NSW, Australia.
C PlummerCentre for Neurosciences and Neurological Research, St Vincent's Hospital Melbourne, Fitzroy, VIC, Australia.
A Van der WaltDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.ORCID https://orcid.org/0000-0002-4278-7003
K MartelNovartis Pharmaceuticals Australia, Macquarie Park, NSW, Australia.
R A WalkerNovartis Pharmaceuticals Australia, Macquarie Park, NSW, Australia.
Novartis (Australia) · AUThe University of Sydney · AUThe University of Queensland · AUConcord Repatriation General Hospital · AUFlinders University · AUGosford Hospital · AUGriffith University · AUJohn Hunter Hospital · AULiverpool Hospital · AUSir Charles Gairdner Hospital · AUSt Vincent's Hospital Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Siponimod is approved for use in people with secondary progressive multiple sclerosis (pwSPMS). An integrated digital platform, MSGo, was developed for pwSPMS and clinicians to help navigate the multiple steps of the pre-siponimod work-up. Objective: To explore real-world onboarding experiences of siponimod amongst pwSPMS in Australia. Methods: Retrospective, non-interventional, longitudinal, secondary analysis of data extracted from MSGo (20 April 2022). The primary endpoint was the average time for siponimod onboarding; secondary endpoints were adherence and sub-group analyses of variables influencing onboarding. Results: Mixed-cure modelling estimated that 58% of participants ( Conclusions: Despite the limitations of self-reported data and the challenges of the COVID-19 pandemic, this study provides insights into siponimod onboarding in Australia and demonstrates the positive impact of care partner support.

Indexed as

Australiahealthcare deliverymedication adherenceMultiple sclerosispatient-reported outcome measuresregression analysissiponimod

Identifiers

PMID38222025
PMCPMC10787529
OpenAlexW4390790754

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.